Literature DB >> 6606577

Interaction of dihydroergotamine and triacetyloleandomycin in the minipig.

M Martinet, J R Kiechel.   

Abstract

The kinetics of unchanged DHE and of the sum of parent drug and metabolites under the effect of acute TO exposure were investigated by comparing the areas under the plasma concentration-time curves after oral, intravenous and hepatoportal administration in minipigs. While TO (500 mg p.o. 15 min. before DHE) caused only a slight increase of plasma levels of parent drug or the sum of parent drug and metabolites after an intravenous dose of 1 mg DHE, there was an important and significant increase of the 0-24 hrs AUC's after administration of (10 mg) oral or (1 mg) hepatoportal DHE. This finding strongly suggests that the interaction TO and DHE occurs at the hepatic site. However, under these experimental conditions, the metabolism of DHE does not seem to be modified by TO administration, an indication that the mechanism of the interaction with TO could be an inhibition of the biliary excretion of DHE and DHE metabolites and/or a release of DHE and metabolites from hepatic binding sites.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6606577     DOI: 10.1007/BF03188756

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  5 in total

1.  [Is triacetyl oleandomycin-ergotamine tartrate combination dangerous?].

Authors:  B Bigorie; P Aimez; R J Soria; F Samama; G di Maria; B Guy-Grand; H Bour
Journal:  Nouv Presse Med       Date:  1975-11-08

2.  [Ischemia of the extremities caused by a combination of dihydroergotamine and triacetyloleandomycin. New case report].

Authors:  F Bacourt; J C Couffinhal
Journal:  Nouv Presse Med       Date:  1978-05-06

3.  [Acute ergotism caused by dihydroergotamine-triacetyloleandomycin association].

Authors:  A Franco; P Bourlard; C Massot; J Lecoeur; H Guidicelli; G Bessard
Journal:  Nouv Presse Med       Date:  1978-01-21

4.  9-10-dihydroergotamine: production of antibodies and radioimmunoassay.

Authors:  J Rosenthaler; H Munzer
Journal:  Experientia       Date:  1976-02-15

5.  Hypoactivity of cytochrome P-450 after triacetyloleandomycin administration.

Authors:  D Pessayre; M Konstantinova-Mitcheva; V Descatoire; B Cobert; J C Wandscheer; R Level; G Feldmann; D Mansuy; J P Benhamou
Journal:  Biochem Pharmacol       Date:  1981-03-15       Impact factor: 5.858

  5 in total
  2 in total

Review 1.  Clinically significant drug interactions with agents specific for migraine attacks.

Authors:  M J Eadie
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 2.  Pharmacokinetic drug interactions of macrolides.

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.